<DOC>
	<DOC>NCT01508364</DOC>
	<brief_summary>This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.</brief_summary>
	<brief_title>Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients with a diagnosis of advanced Renal cell carcinoma (RCC) for whom the decision has been taken by the investigator to prescribe Nexavar. Patients who failed cytokine therapy or who are not suitable for cytokines for whom Nexavar is the first targeted drug treatment. Prior targeted therapy for RCC Contraindications of Nexavar described in the Summary of Product Characteristics (SPC).</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>renal cell carcinoma, first targeted therapy, observational study</keyword>
</DOC>